San Francisco startup Construction Therapeutics can also be working on an oral, after-daily GLP-one drug called GSBR-1290—the drug surpassed Wall Avenue’s expectations in June when a mid-phase analyze confirmed average weight loss of all-around six% and it programs to get started on